Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Melike Sezgin Evim is active.

Publication


Featured researches published by Melike Sezgin Evim.


Pediatric Neurology | 2010

Reversible Posterior Leukoencephalopathy Induced by Cancer Chemotherapy

Birol Baytan; Özlem Özdemir; Metin Demirkaya; Melike Sezgin Evim; Adalet Meral Gunes

Reversible posterior leukoencephalopathy, defined by both clinical and neuroimaging findings, can affect children receiving chemotherapy. The syndrome is characterized by hypertension, alterations in mental status, seizures, hallucinations, and acute visual changes and is associated with abnormalities seen in magnetic resonance imaging of symmetric white matter lesions, especially in the parietal and occipital lobes. The etiology of reversible posterior leukoencephalopathy is as yet unknown. Presented here are four cases of reversible posterior leukoencephalopathy induced by chemotherapy, with a brief review of the literature and consideration of possible mechanisms. A diagnosis of reversible posterior leukoencephalopathy should be considered when patients receiving cancer chemotherapy suddenly develop hypertension followed by neurologic complications, especially if presenting with seizures.


Turkish Journal of Hematology | 2014

Childhood Immune Thrombocytopenia: Long-term Follow-up Data Evaluated by the Criteria of the International Working Group on Immune Thrombocytopenic Purpura

Melike Sezgin Evim; Birol Baytan; Adalet Meral Gunes

Objective: Immune thrombocytopenia (ITP) is a common bleeding disorder in childhood, characterized by isolated thrombocytopenia. The International Working Group (IWG) on ITP recently published a consensus report about the standardization of terminology, definitions, and outcome criteria in ITP to overcome the difficulties in these areas. Materials and Methods: The records of patients were retrospectively collected from January 2000 to December 2009 to evaluate the data of children with ITP by using the new definitions of the IWG. Results: The data of 201 children were included in the study. The median follow-up period was 22 months (range: 12-131 months). The median age and platelet count at presentation were 69 months (range: 7-208 months) and 19x109/L (range: 1x109/L to 93x109/L), respectively. We found 2 risk factors for chronic course of ITP: female sex (OR=2.55, CI=1.31-4.95) and age being more than 10 years (OR=3.0, CI=1.5-5.98). Life-threatening bleeding occurred in 5% (n=9) of the patients. Splenectomy was required in 7 (3%) cases. When we excluded 2 splenectomized cases, complete remission at 1 year was achieved in 70% (n=139/199). The disease was resolved in 9 more children between 12 and 90 months. Conclusion: Female sex and age above 10 years old significantly influenced chronicity. Therefore, long-term follow-up is necessary in these children.


Pediatric Neurology | 2015

Acute Central Nervous System Complications in Pediatric Acute Lymphoblastic Leukemia

Birol Baytan; Melike Sezgin Evim; Salih Güler; Adalet Meral Gunes; Mehmet Okan

BACKGROUND The outcome of childhood acute lymphoblastic leukemia has improved because of intensive chemotherapy and supportive care. The frequency of adverse events has also increased, but the data related to acute central nervous system complications during acute lymphoblastic leukemia treatment are sparse. The purpose of this study is to evaluate these complications and to determine their long term outcome. PATIENTS AND METHODS We retrospectively analyzed the hospital reports of 323 children with de novo acute lymphoblastic leukemia from a 13-year period for acute neurological complications. The central nervous system complications of leukemic involvement, peripheral neuropathy, and post-treatment late-onset encephalopathy, and neurocognitive defects were excluded. RESULTS Twenty-three of 323 children (7.1%) suffered from central nervous system complications during acute lymphoblastic leukemia treatment. The majority of these complications (n = 13/23; 56.5%) developed during the induction period. The complications included posterior reversible encephalopathy (n = 6), fungal abscess (n = 5), cerebrovascular lesions (n = 5), syndrome of inappropriate secretion of antidiuretic hormone (n = 4), and methotrexate encephalopathy (n = 3). Three of these 23 children (13%) died of central nervous system complications, one from an intracranial fungal abscess and the others from intracranial thrombosis. Seven of the survivors (n = 7/20; 35%) became epileptic and three of them had also developed mental and motor retardation. CONCLUSIONS Acute central neurological complications are varied and require an urgent approach for proper diagnosis and treatment. Collaboration among the hematologist, radiologist, neurologist, microbiologist, and neurosurgeon is essential to prevent fatal outcome and serious morbidity.


Clinical and Applied Thrombosis-Hemostasis | 2013

Thrombolysis with recombinant tissue plasminogen activator in 7 children.

Melike Sezgin Evim; Özlem M. Bostan; Birol Baytan; Evren Semizel; Adalet Meral Gunes

The information about the thromboembolic events, the optimal treatment choice, the dose, and duration of antithrombotic therapy in children are limited. More clinical data are required. Recombinant tissue plasminogen activator (r-tPA) is increasingly used in pediatric thrombosis. We retrospectively analyzed the clinical course of 7 children (9.3 ± 2.1 years; 34 days to 16 years) with arterial thrombosis (n = 1) and intracardiac thrombosis (n = 6). The children were treated with r-tPA. The dose ranged between 0.2 and 0.4 mg/kg per h infused for 3 to 4 hours. This dose was repeated between 2 to 7 times till the thrombolysis was achieved. Treatment side effects were closely monitored. Complete clot lysis was achieved in all cases. None of them had severe bleeding except mild recurrent epistaxis occurring in 2 cases. In conclusion, r-tPA is an effective and safe therapy under close hemostatic control in children.


Turkish Journal of Hematology | 2017

A national registry of thalassemia in Turkey; demographic and disease characteristics of patients, achievements and challenges in prevention

Yesim Aydinok; Yeşim Oymak; Berna Atabay; Gonul Aydogan; Akif Yesilipek; Selma Unal; Yurdanur Kilinç; Banu Oflaz; Mehmet Akin; Canan Vergin; Melike Sezgin Evim; Umran Caliskan; Şule Ünal; Ali Bay; Elif Kazancı; Dilber Talia Ileri; Didem Atay; Turkan Patiroglu; Selda Kahraman; Murat Söker; Mediha Akcan; Aydan Akdeniz; Mustafa Buyukavci; Güçhan Alanoğlu; Özcan Bör; Nur Soyer; Nihal Karadaş; Ezgi Uysalol; Meral Türker; Arzu Akcay

Objective: The Turkish Society of Pediatric Hematology set up a National Hemoglobinopathy Registry to demonstrate the demographic and disease characteristics of patients and assess the efficacy of a hemoglobinopathy control program (HCP) over 10 years in Turkey. Materials and Methods: A total of 2046 patients from 27 thalassemia centers were registered, of which 1988 were eligible for analysis. This cohort mainly comprised patients with β-thalassemia major (n=1658, 83.4%) and intermedia (n=215, 10.8%). Results: The majority of patients were from the coastal areas of Turkey. The high number of patients in Southeastern Anatolia was due to that area having the highest rates of consanguineous marriage and fertility. The most common 11 mutations represented 90% of all β-thalassemia alleles and 47% of those were IVS1-110(G->A) mutations. The probability of undergoing splenectomy within the first 10 years of life was 20%, a rate unchanged since the 1980s. Iron chelators were administered as monotherapy regimens in 95% of patients and deferasirox was prescribed in 81.3% of those cases. Deferasirox administration was the highest (93.6%) in patients aged <10 years. Of the thalassemia major patients, 5.8% had match-related hemopoietic stem cell transplantation with a success rate of 77%. Cardiac disease was detected as a major cause of death and did not show a decreasing trend in 5-year cohorts since 1999. Conclusion: While the HCP has been implemented since 2003, the affected births have shown a consistent decrease only after 2009, being at lowest 34 cases per year. This program failure resulted from a lack of premarital screening in the majority of cases. Additional problems were unawareness of the risk and misinformation of the at-risk couples. In addition, prenatal diagnosis was either not offered to or was not accepted by the at-risk families. This study indicated that a continuous effort is needed for optimizing the management of thalassemia and the development of strategies is essential for further achievements in the HCP in Turkey.


Turkish journal of haematology : official journal of Turkish Society of Haematology | 2012

Cerebellar granulocytic sarcoma: a case report.

Birol Baytan; Melike Sezgin Evim; Adalet Meral Gunes; Hasan Kocaeli; Saduman Balaban; Ender Korfali; Nukhet Tuzuner

Granulocytic sarcoma is a rare tumor composed of immature granulocytic cells that is usually associated with acute myelogenous leukemia. Intraparenchymal cranial localization without skull, meningeal, or bone marrow invasion is extremely rare. The mechanisms of intraparenchymal cranial localization of GS remains unknown, as only 10 cases with cerebellar granulocytic sarcoma have been previously reported. Herein, we report a four year old boy with cerebellar localization of granulocytic sarcoma.


Turkish Journal of Hematology | 2017

Juvenile Myelomonocytic Leukemia in Turkey: A Retrospective Analysis of 65 Patients

Özlem Tüfekçi; Şebnem Yılmaz Bengoa; Hale Ören; Ulker Kocak; Zühre Kaya; Idil Yenicesu; Canan Albayrak; Davut Albayrak; Turkan Patiroglu; Musa Karakukcu; Ekrem Unal; Elif İnce; Talia Ileri; Mehmet Ertem; Tiraje Celkan; Gül Nihal Özdemir; Nazan Sarper; Dilek Kaçar; Nese Yarali; Namık Yaşar Özbek; Alphan Kupesiz; Tuba Hilkay Karapınar; Canan Vergin; Umran Caliskan; Huseyin Tokgoz; Melike Sezgin Evim; Birol Baytan; Adalet Meral Gunes; Deniz Yilmaz Karapinar; Serap Karaman

Objective: This study aimed to define the status of juvenile myelomonocytic leukemia (JMML) patients in Turkey in terms of time of diagnosis, clinical characteristics, mutational studies, clinical course, and treatment strategies. Materials and Methods: Data including clinical and laboratory characteristics and treatment strategies of JMML patients were collected retrospectively from pediatric hematology-oncology centers in Turkey. Results: Sixty-five children with JMML diagnosed between 2002 and 2016 in 18 institutions throughout Turkey were enrolled in the study. The median age at diagnosis was 17 months (min-max: 2-117 months). Splenomegaly was present in 92% of patients at the time of diagnosis. The median white blood cell, monocyte, and platelet counts were 32.9x109/L, 5.4x109/L, and 58.3x109/L, respectively. Monosomy 7 was present in 18% of patients. JMML mutational analysis was performed in 32 of 65 patients (49%) and PTPN11 was the most common mutation. Hematopoietic stem cell transplantation (HSCT) could only be performed in 28 patients (44%), the majority being after the year 2012. The most frequent reason for not performing HSCT was the inability to find a suitable donor. The median time from diagnosis to HSCT was 9 months (min-max: 2-63 months). The 5-year cumulative survival rate was 33% and median estimated survival time was 30±17.4 months (95% CI: 0-64.1) for all patients. Survival time was significantly better in the HSCT group (log-rank p=0.019). Older age at diagnosis (>2 years), platelet count of less than 40x109/L, and PTPN11 mutation were the factors significantly associated with shorter survival time. Conclusion: Although there has recently been improvement in terms of definitive diagnosis and HSCT in JMML patients, the overall results are not satisfactory and it is necessary to put more effort into this issue in Turkey.


Annals of Hematology | 2014

The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol

Adalet Meral Gunes; Hale Ören; Birol Baytan; Şebnem Yılmaz Bengoa; Melike Sezgin Evim; Salih Gözmen; Özlem Tüfekçi; Tuba Hilkay Karapınar; Gülersu Irken


Journal of Aapos | 2017

Spectral domain optical coherence tomography findings of patients under treatment for pediatric acute lymphoblastic leukemia

Ozgur Yalcinbayir; Birol Baytan; Oner Gelisken; Basak Can; Melike Sezgin Evim; Meral Yıldız; Adalet Meral Gunes


Güncel Pediatri | 2017

Adölesan Dönemi Beslenme ve Sorunları Nutrition and Issues in Adolescence Period

Melike Sezgin Evim; Birol Baytan; Adalet Meral Gunes

Collaboration


Dive into the Melike Sezgin Evim's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Hale Ören

Dokuz Eylül University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Canan Vergin

Boston Children's Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge